CVS is now covering long-acting injectable PrEP, representing a shift from last year when the pharmacy giant announced it was ...

The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an injectable form of the HIV prevention medication known as PrEP, marking a ...

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...

Lynne Milgram, MD, MBA, CPE: The conversation needs to begin with the health care provider and the patient, and a good history has to be taken. It needs to be joint decision-making, clinical ...

Share on Pinterest Research finds a new injectable form of PrEP is superior to daily oral tablets to prevent the contraction of HIV. Sara Jurado/Getty Images New research sheds light on the efficacy ...

Lenacapavir, a long-acting injectable PrEP, requires two injections annually, marking a significant advancement in HIV ...

Kenya will this year begin rolling out a new long-acting injectable HIV prevention drug, Lenacapavir, positioning the country ...

The burden of taking a daily dose of PrEP might soon be lifted. According to updated CDC guidelines, bi-monthly injectable PrEP is expected to receive FDA approval by February. The injectable ...

Please provide your email address to receive an email when new articles are posted on . Injectable cabotegravir administered every 8 weeks was associated with approximately nine times fewer HIV ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...